EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

AA Amyloidosis: A Contemporary View

Safak Mirioglu, Omer Uludag, Ozge Hurdogan, Gizem Kumru, Ilay Berke, Stavros A Doumas, Eleni Frangou, Ahmet Gul

Current Rheumatology Reports · 2024-07 · 26 (7) · 248-259

DOI: 10.1007/s11926-024-01147-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Rheumatology Reports, online erschienen am 03.04.2024. Verfasst von Safak Mirioglu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. smirioglu@gmail.com. Hauptthemen laut MEDLINE: Amyloidosis. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Istanbul University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose of Review Amyloid A (AA) amyloidosis is an organ- or life-threatening complication of chronic inflammatory disorders. Here, we review the epidemiology, causes, pathogenesis, clinical features, and diagnostic and therapeutic strategies of AA amyloidosis. Recent Findings The incidence of AA amyloidosis has declined due to better treatment of the underlying diseases. Histopathological examination is the gold standard of diagnosis, but magnetic resonance imaging can be used to detect cardiac involvement. There is yet no treatment option for the clearance of amyloid fibril deposits; therefore, the management strategy primarily aims to reduce serum amyloid A protein. Anti-inflammatory biologic agents have drastically expanded our therapeutic armamentarium. Kidney transplantation is preferred in patients with kidney failure, and the recurrence of amyloidosis in the allograft has become rare as transplant recipients have started to benefit from the new agents. Summary The management of AA amyloidosis has been considerably changed over the recent years due to the novel therapeutic options aiming to control inflammatory activity. New agents capable of clearing amyloid deposits from the tissues are still needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmyloidosisHumansSerum Amyloid A ProteinKidney Transplantation

Stichwörter der Autor:innen

AmyloidosisArthritisAutoinflammatory diseasesChronic infectionChronic inflammationSerum amyloid A

Substanzen

Serum Amyloid A Protein

Autor:innen und Institutionen

  • Division of Nephrology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. smirioglu@gmail.com.
  • Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey. smirioglu@gmail.com.
  • Division of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Division of Nephrology, Ankara University Faculty of Medicine, Ankara, Turkey.
  • Division of Nephrology, Marmara University School of Medicine, Istanbul, Turkey.

Förderung

  • Istanbul University

Zitieren

APA

Mirioglu, S., Uludag, O., Hurdogan, O., Kumru, G., Berke, I., Doumas, S. A., Frangou, E., & Gul, A. (2024). AA Amyloidosis: A Contemporary View. Current Rheumatology Reports, 26(7), 248-259. https://doi.org/10.1007/s11926-024-01147-8

Vancouver

Mirioglu S, Uludag O, Hurdogan O, Kumru G, Berke I, Doumas SA, et al. AA Amyloidosis: A Contemporary View. Current Rheumatology Reports. 2024;26(7):248-259. doi:10.1007/s11926-024-01147-8

BibTeX
@article{Mirioglu2024,
  author = {Mirioglu, Safak and Uludag, Omer and Hurdogan, Ozge and Kumru, Gizem and Berke, Ilay and Doumas, Stavros A and Frangou, Eleni and Gul, Ahmet},
  title = {AA Amyloidosis: A Contemporary View},
  journal = {Current Rheumatology Reports},
  year = {2024},
  volume = {26},
  number = {7},
  pages = {248--259},
  doi = {10.1007/s11926-024-01147-8}
}
Kostenlos starten →